MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Home・Akciju saraksts・Cogent Biosciences Inc

Cogent Biosciences Inc

Slēgts

35.28 -0.17

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

35.17

Max

36.84

Galvenie mērījumi
By Trading Economics
Ienākumi	-7.4M -81M
EPS	-0.5
Darbinieki	205
EBITDA	-6.8M -79M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+36.91% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 24. febr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	3.1B 5.3B
Iepriekšējā atvēršanas cena	35.45
Iepriekšējā slēgšanas cena	35.28

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

4.88 / 5.87 Atbalsts un pretestība

Cogent Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 9. janv. 22:18 UTC

Tirgus saruna

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

2026. g. 9. janv. 21:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 9. janv. 21:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Basic Materials Roundup: Market Talk

2026. g. 9. janv. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 9. janv. 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 9. janv. 21:43 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

2026. g. 9. janv. 20:39 UTC

Tirgus saruna

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

2026. g. 9. janv. 20:38 UTC

Tirgus saruna

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

2026. g. 9. janv. 20:36 UTC

Iegādes, apvienošanās, pārņemšana

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

2026. g. 9. janv. 20:30 UTC

Tirgus saruna

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

2026. g. 9. janv. 20:15 UTC

Tirgus saruna

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

2026. g. 9. janv. 20:07 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 9. janv. 20:07 UTC

Tirgus saruna

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

2026. g. 9. janv. 19:58 UTC

Iegādes, apvienošanās, pārņemšana

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

2026. g. 9. janv. 19:42 UTC

Tirgus saruna

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

2026. g. 9. janv. 19:38 UTC

Iegādes, apvienošanās, pārņemšana

Wolters Kluwer Acquires StandardFusion >WTKWY

2026. g. 9. janv. 19:31 UTC

Peļņas

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

2026. g. 9. janv. 19:28 UTC

Peļņas

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

2026. g. 9. janv. 18:30 UTC

Tirgus saruna

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

2026. g. 9. janv. 18:23 UTC

Tirgus saruna

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

2026. g. 9. janv. 17:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Basic Materials Roundup: Market Talk

2026. g. 9. janv. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 9. janv. 17:19 UTC

Tirgus saruna

Energy Prices Not Seen Supporting More Drilling -- Market Talk

2026. g. 9. janv. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 9. janv. 17:07 UTC

Tirgus saruna

McDonald's Promotions Appear Successful -- Market Talk

2026. g. 9. janv. 17:06 UTC

Tirgus saruna

Oil Futures on Track for Weekly Gains -- Market Talk

2026. g. 9. janv. 17:05 UTC

Peļņas

Stocks Sail Past Jobs Data, Tariff Opinion Delay. Earnings Season Looms. -- Barrons.com

2026. g. 9. janv. 16:57 UTC

Tirgus saruna

Energy Activity Tumbles in 4Q, KC Fed Survey Finds -- Market Talk

2026. g. 9. janv. 16:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 9. janv. 16:46 UTC

Tirgus saruna

Dollar Could Stay Steady For Now, More Likely to Fall Than Rise -- Market Talk

Salīdzinājums

Cenas izmaiņa

Cogent Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

36.91% augšup

Prognoze 12 mēnešiem

Vidējais 48.7 USD 36.91%

Augstākais 67 USD

Zemākais 34 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

11 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 11 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.88 / 5.87Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.